# A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)

> **NCT07743190** · PHASE2 · RECRUITING · sponsor: **Medical University of South Carolina** · enrollment: 55 (estimated)

## Conditions studied

- Triple Negative Breast Cancer (TNBC)
- Elevated Tumor-Infiltrating Lymphocytes

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Paclitaxcel
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07743190
- **Lead sponsor:** Medical University of South Carolina
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2029-03-01
- **Final completion:** 2030-03-01
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2026-08-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07743190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07743190, "A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07743190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*